Literature DB >> 32709256

Triglyceride-glucose index (TyG index) is a predictor of incident colorectal cancer: a population-based longitudinal study.

Takuro Okamura1, Yoshitaka Hashimoto1, Masahide Hamaguchi2, Akihiro Obora3, Takao Kojima3, Michiaki Fukui1.   

Abstract

BACKGROUND: Colorectal cancer (CRC), which is related with insulin resistance, is a one of the most common cancers. Triglyceride-glucose index (TyG index) was made for a marker of insulin resistance. We conducted the investigation of association between TyG index and incident CRC.
METHODS: We examined the affect of TyG index on incident CRC in this historical cohort study of 27,944 (16,454 men and 11,490 women) participants. TyG index was calculated as ln [fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL)/2]. The impact of TyG index on incident CRC was investigated using Cox proportional hazard models, adjusting for sex, age, body mass index, smoking status, alcohol consumption, exercise, systolic blood pressure and creatinine. The covariate-adjusted receiver operating characteristic (ROC) curve calculated the area under the curve (AUC) and cut-off value of TyG index for the incidence of CRC.
RESULTS: During the median 4.4-year follow-up, 116 participants were diagnosed as CRC. The cumulative incidence rate of CRC were 0.4%. In Cox proportional hazard model, the HRs of TyG index were 1.38 (95% Confidence interval (CI), 1.00-1.91, p = 0.049) after adjusting for covariates. In the covariate-adjusted ROC curve analysis, the cut-off value of TyG index for incident CRC was 8.272 (AUC 0.687 (95%CI, 0.637-737, sensitivity = 0.620, specificity = 0.668, p < 0.001)).
CONCLUSIONS: TyG index can predict the onset of CRC. For early detection of CRC, we should encourage people with high TyG index to undergo screening for CRC.

Entities:  

Keywords:  Cohort study; Colorectal cancer; Epidemiology; Insulin resistance; TyG index

Mesh:

Substances:

Year:  2020        PMID: 32709256      PMCID: PMC7379831          DOI: 10.1186/s12902-020-00581-w

Source DB:  PubMed          Journal:  BMC Endocr Disord        ISSN: 1472-6823            Impact factor:   2.763


Background

Colorectal cancer (CRC) is the third leading cause of the most common cancers next to lung and breast cancer in the world [1]. The most efficient strategies in reducing incident CRC are identification of patients with high-risk for CRC and performing colonoscopy. Metabolic syndrome, i.e. obesity, impaired glucose tolerance, hypertension and dyslipidemia, has been reported to be associated with risk of CRC by several studies [2-6]. Particularly, insulin resistance is associated with hyperinsulinemia [7, 8], increased levels of insulin-like growth factors (IGF) [9, 10], and alterations in necrosis factor (NF)-κB [11] and peroxisome proliferator-activated receptor gamma (PPARγ) signaling [12], which plays a key role in the pathogenesis of CRC [13-15]. Triglyceride-glucose index (TyG index) was made for a marker of insulin resistance, and calculated with fasting plasma glucose and triglycerides [16, 17]. .In addition, several groups demonstrated that TyG index could predict the incidence of type 2 diabetes [18, 19] and cardiovascular disease [20]. Thus, we hypothesized that TyG index can predict the incidence of CRC. However, no previous studies have investigated this association. We conducted the investigation of association between TyG index and incident CRC in this retrospective study.

Methods

Study participants and study design

This was a retrospective sub-analysis of the ongoing cohort study named NAGALA (NAfld in the Gifu Area, Longitudinal Analysis) study, which is a medical checkup program and a cohort investigation that has been ongoing at Asahi University Hospital (Gifu, Japan). The impact of TyG index on the risk of incident CRC was investigated in this NAGALA study. This investigation has been ongoing and aims to detect chronic diseases and their risk factors, and to promote public health. The detail of NAGALA study and medical examination programs were expressed in our previous study [21]. We recruited the participants in this medical examination program from 2003 to 2016. The exclusion criteria were follows: the participants whose data, including smoking status and alcohol consumption, were missed. The informed consent to participate was provided from all patients in this sub-analysis of NAGALA study. The present study was approved by each hospital’s Ethics Committee.

Data collection and measurements

In a standardized self-administered questionnaire, the medical background and the data of alcohol consumption, smoking status and physical activity were taken from all of the participants [21]. In the questionnaire, we asked about the type and amount of alcohol consumption per week during the prior month, then we estimated the mean ethanol intake per week. The participants were categorized into the following four groups: no or minimal alcohol consumer, < 40 g/week; light, 40–140 g/week; moderate, 140–280 g/week; or heavy alcohol consumer, > 280 g/week [22]. In addition, the participants were categorized into the following three groups by smoking status: non-, ex-, or current smoker. Furthermore, we also asked participants’ recreational activities and sports activities by questionnaire. We defined regular exercisers as individuals regularly over one time per week playing any type of sports [23]. Lastly, TyG index was calculated as ln [fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL)/2] [16].

Identification of cases of colorectal cancer

We performed fecal occult blood test in this health checkup program. When the fecal occult test was positive and the presence of CRC was suspected, the staffs informed and recommended participants to receive further examinations such as lower gastrointestinal endoscopy. We gathered the medical information regarding colorectal cancers by a standardized letter from a hospital where a participant receives further examinations. Besides, we included participants who received further examinations for reasons other than occult blood test and were diagnosed as colorectal cancer. The gastroenterologist checked the gathered information and defined them as colorectal cancer. From Jan 1st 2004, we adopted the standardized letter. Then, we set the study period as Jan 1st 2004 to Dec 31st 2016. The primary endpoint in this study was set as incident CRC. In this study, we defined the day when participants were suggested as cancer at the health checkup center as the onset day if participants were diagnosed as CRC.

Statistical analysis

We performed the following analyses with the JMP software ver. 13.0 (SAS, Cary, NC, USA). A p-value was considered to indicate a significant when it was less than 0.05. We expressed values as mean (SD) or median (interquartile) for continuous variables and number (%) for categorial variables. The baseline characteristics of participants who developed CRC and those who did not were investigated. The p values were calculated uby one-way analysis of variance (ANOVA) for continuous variables and chi-squared test for categorical variables, respectively. Cox proportional hazards models were used to estimate hazard ratio (HR) and 95% confidence interval (CI) for incident CRC. In Model 1, we unadjusted, in Model 2, we adjusted for sex and age, and, in Model 3, we adjusted for Model 2 and body mass index, smoking status, alcohol consumption, exercise habit, systolic blood pressure and serum creatinine. Additionally, the covariate-adjusted receiver operating characteristic (ROC) curve calculated the area under the curve (AUC) and cut-off value of TyG index for the incidence of CRC, and the AUC of TyG index was compared with those of BMI, brinkman index, alcohol consumption, total cholesterol, and triglycerides.

Results

From Jan 1st in 2004 to Dec 31st in 2016, 27,944 participants (16,454 men and 11,490 women) were registered in NAGALA cohort. After excluding those who met exclusion criteria, 27,921 participants (16,434 men and 11,487 women) were entered (Fig. 1). The baseline characteristics of the participants are shown in Table 1. Mean (± standard deviation) age of participants was 45.7 ± 10.1 years old and BMI was 22.6 ± 3.3 kg/m2.
Fig. 1

Study flow diagram for the registration of participants

Table 1

Clinical characteristics of participants

Total (n = 27,921)
Sex, men/women16,434/11,487
Age, yrs45.7 (10.1)
BMI, kg/m222.6 (3.3)
WC, cm78.1 (9.6)
Ex-smoker6185 (22.2)
Current-smoker6921 (24.9)
Regular exerciser4984 (18.0)
Light alcohol consumer2984 (10.8)
Moderate alcohol consumer2577 (9.3)
Heavy alcohol consumer2198 (8.0)
Fasting plasma glucose, mmol/L5.3 (0.7)
HbA1c, %5.3 (0.6)
HbA1c, mmol/mol34.6 (5.4)
Triglycerides, mmol/L1.0 (0.9)
Total cholesterol, mmol/L5.2 (0.9)
HDL cholesterol, mmol/L1.4 (0.4)
AST, IU/L19.5 (9.7)
ALT, IU/L21.5 (15.2)
GGT, IU/L23.6 (25.3)
SBP, mmHg117.7 (16.4)
DBP, mmHg73.6 (11.2)
Creatinine, Creatinine, μmol/L73.0 (22.8)
TyG index8.2 (0.7)

ALT alanine transaminase, AST aspartate transaminase, BMI body mass index, DBP diastolic blood pressure, GGT γ-glutamyltransferase, HbA1c hemoglobin A1c, HDL high density lipoprotein, SBP systolic blood pressure, TyG index triglyceride–glucose index, WC waist circumference

Data are mean (SD) or number

Study flow diagram for the registration of participants Clinical characteristics of participants ALT alanine transaminase, AST aspartate transaminase, BMI body mass index, DBP diastolic blood pressure, GGT γ-glutamyltransferase, HbA1c hemoglobin A1c, HDL high density lipoprotein, SBP systolic blood pressure, TyG index triglycerideglucose index, WC waist circumference Data are mean (SD) or number Participants who developed CRC were older than those who did not (51.1 ± 9.3 vs 45.6 ± 10.1 years, p < 0.001). Next, alcohol consumption of participants who developed CRC was greater than that of those who did not. In the metabolic status, fasting plasma glucose, hemoglobin A1c, triglycerides, total cholesterol, serum creatinine, and systolic and diastolic blood pressure of participants who developed CRC were higher than those of participants who did not (Table 2).
Table 2

Clinical characteristics of participants

CRC (−)(n = 27,805)CRC (+)(n = 116)P-value
Sex, men/women16,353/11,45281/350.014
Age, yrs45.6 (10.1)51.1 (9.3)< 0.001
BMI, kg/m222.6 (3.3)23.1 (3.5)0.084
WC, cm78.0 (9.6)80.5 (8.9)0.006
Smoking status0.003
 Non-smoker14,772 (53.0)43 (37.1)
 Ex-smoker6150 (22.1)35 (30.2)
 Current smoker6883 (24.8)38 (32.8)
Regular exerciser4964 (18.0)20 (17.5)0.905
Alcohol consumption< 0.001
 Light alcohol consumer4682 (17.0)23 (20.0)
 Moderate alcohol consumer2560 (9.3)17 (14.8)
 Heavy alcohol consumer2177 (7.9)21 (18.3)
Fasting plasma glucose, mmol/L5.4 (1.0)5.7 (1.4)0.004
HbA1c, %5.3 (0.6)5.4 (0.8)0.042
HbA1c, mmol/mol34.6 (6.8)35.9 (8.2)0.042
Triglycerides, mmol/L1.0 (0.9)1.3 (1.0)0.002
Total cholesterol, mmol/L5.2 (0.9)5.4 (0.9)0.011
HDL cholesterol, mmol/L1.4 (0.4)1.3 (0.4)0.012
Creatinine, μmol/L73.0 (22.8)76.7 (16.1)0.039
AST, IU/L19.5 (9.7)19.1 (7.6)0.664
ALT, IU/L21.5 (15.2)20.9 (9.2)0.689
GGT, IU/L23.6 (25.2)28.1 (32.3)0.053
SBP, mmHg117.7 (16.4)121.2 (17.1)0.018
DBP, mmHg73.6 (11.2)76.7 (11.0)0.004
TyG index8.2 (0.7)8.4 (0.7)< 0.001

ALT alanine transaminase, AST aspartate transaminase, BMI body mass index, CRC colorectal cancer, DBP diastolic blood pressure, GGT γ-glutamyltransferase, HbA1c hemoglobin A1c, HDL high density lipoprotein, SBP systolic blood pressure, TyG index triglyceride–glucose index, WC: waist circumference

Data are mean (SD) or number

Clinical characteristics of participants ALT alanine transaminase, AST aspartate transaminase, BMI body mass index, CRC colorectal cancer, DBP diastolic blood pressure, GGT γ-glutamyltransferase, HbA1c hemoglobin A1c, HDL high density lipoprotein, SBP systolic blood pressure, TyG index triglycerideglucose index, WC: waist circumference Data are mean (SD) or number One hundred sixteen participants were diagnosed as CRC during the median 4.4-year follow-up. The cumulative incidence rate of CRC was 0.4%. In Cox proportional hazard model, the HRs of TyG index were 1.65 (95%CI 1.29–2.13, p < 0.001) in Model 1, 1.41 (1.05–1.89, p = 0.021) in Model 2 and 1.36 (1.00–1.86, p = 0.049) in Model 3 (Table 3 qaxzdf). Moreover, the cut-off value of TyG index for incident CRC was 8.272 in the covariate-adjusted ROC curve analysis (AUC 0.687 (95%CI, 0.637–0.737, sensitivity = 0.620, specificity = 0.668, p < 0.001)). Additionally, we also calculated AUC of BMI (0.547, 95% CI: 0.498–0.602, p < 0.001, vs. TyG index), that of brinkman index (0.605, 95% CI: 0.551–0.654, p < 0.001, vs. TyG index), that of alcohol consumption (0.623, 95% CI: 0.571–0.676, p < 0.001, vs. TyG index), that of TC (0.563, 95% CI: 0.515–0.616, p < 0.001, vs. TyG index), and that of TG (0.608, 95% CI: 0.560–0.658, p < 0.001, vs. TyG index), respectively (Fig. 2). TyG index had a significantly higher AUC for the development of CRC than the other risk factors.
Table 3

Cox proportional hazards for incident colorectal cancer

Model 1Model 2Model 3
HR (95% CI)p-valueHR (95% CI)p-valueHR (95% CI)p-value
Men1.09 (0.71–1.70)0.7121.01 (0.59–1.84)0.975
Age, years1.07 (1.05–1.09)< 0.0011.07 (1.04–1.09)< 0.001
BMI, kg/m20.99 (0.93–1.07)0.912
Ex-smoker1.48 (0.84–2.61)0.176
Current smoker1.55 (0.87–2.75)0.117
Light alcohol consumer1.32 (0.77–2.24)0.298
Moderate alcohol consumer1.55 (0.87–2.75)0.137
Heavy alcohol consumer2.02 (1.14–3.57)0.016
Regular exerciser0.79 (0.46–1.29)0.360
Systolic blood pressure, mmHg0.99 (0.99–1.01)0.987
Creatinine, μmol/L0.85 (0.25–2.89)0.794
TyG index1.65 (1.29–2.13)< 0.0011.41 (1.05–1.89)0.0211.38 (1.00–1.91)0.049

BMI body mass index, TyG index triglyceride-glucose index. Exercise was defined as nonregular exerciser (0) or regular exerciser (1), smoking status was defined as nonsmoker (0), ex-smoker (1) or current smoker (2), and alcohol consumption was defined as no or minimal alcohol consumer (0), light alcohol consumer (1), moderate alcohol consumer (2) and heavy alcohol consumer (3). Model 1 was unadjusted. Model 2 was adjusted for sex and age. Model 3 was adjusted for sex, age, body mass index, smoking status, alcohol consumption, exercise, systolic blood pressure and serum creatinine

Fig. 2

Area under the covariate-adjusted receiver operating characteristic curve (AUC) for predicting incident colorectal cancer (CRC). a.TyG index, b. BMI, c. brinkman index, d. alcohol consumption, e. TC, f. TG. The optimal cut-off value of TyG index for incident CRC is 8.272 (AUC 0.687 (95%CI, 0.637–737, sensitivity = 0.620, specificity = 0.668, p < 0.001)). AUC of BMI was 0.547 (95% CI: 0.498–0.602, p < 0.001, vs. TyG index), that of brinkman index was 0.605 (95% CI: 0.551–0.654, p < 0.001, vs. TyG index), that of alcohol consumption was 0.623 (95% CI: 0.571–0.676, p < 0.001, vs. TyG index), that of TC was 0.563 (95% CI: 0.515–0.616, p < 0.001, vs. TyG index), and that of TG was 0.608 (95% CI: 0.560–0.658, p < 0.001, vs. TyG index), respectively

Cox proportional hazards for incident colorectal cancer BMI body mass index, TyG index triglyceride-glucose index. Exercise was defined as nonregular exerciser (0) or regular exerciser (1), smoking status was defined as nonsmoker (0), ex-smoker (1) or current smoker (2), and alcohol consumption was defined as no or minimal alcohol consumer (0), light alcohol consumer (1), moderate alcohol consumer (2) and heavy alcohol consumer (3). Model 1 was unadjusted. Model 2 was adjusted for sex and age. Model 3 was adjusted for sex, age, body mass index, smoking status, alcohol consumption, exercise, systolic blood pressure and serum creatinine Area under the covariate-adjusted receiver operating characteristic curve (AUC) for predicting incident colorectal cancer (CRC). a.TyG index, b. BMI, c. brinkman index, d. alcohol consumption, e. TC, f. TG. The optimal cut-off value of TyG index for incident CRC is 8.272 (AUC 0.687 (95%CI, 0.637–737, sensitivity = 0.620, specificity = 0.668, p < 0.001)). AUC of BMI was 0.547 (95% CI: 0.498–0.602, p < 0.001, vs. TyG index), that of brinkman index was 0.605 (95% CI: 0.551–0.654, p < 0.001, vs. TyG index), that of alcohol consumption was 0.623 (95% CI: 0.571–0.676, p < 0.001, vs. TyG index), that of TC was 0.563 (95% CI: 0.515–0.616, p < 0.001, vs. TyG index), and that of TG was 0.608 (95% CI: 0.560–0.658, p < 0.001, vs. TyG index), respectively

Discussion

In this retrospective cohort study of over 27,000 Japanese participants, we investigated the affect of TyG index on incidence of CRC and, for the first time, demonstrated that TyG index could predict incidence of CRC. TyG index, calculated with fasting triglycerides and plasma glucose, was originally proposed as a biomarker of insulin resistance [16, 17], and some following studies demonstrated TyG index could predict the incidence of type 2 diabetes [18, 19] and cardiovascular disease [20]. In addition, we showed that the value of TyG index of 8.272 was a cut-off value for incident of CRC. In fact, we compared area under the curve (AUC) of TyG index with that of the known risk factors of the CRC: BMI, smoking, alcohol consumption [24], TC, and TG [25]. Then, TyG index was superior to other markers. Several human studies previously reported the association between insulin resistance and risk of colorectal cancer [13-15]. Similarly, several basic researches revealed that insulin resistance was reported to be associated with hyperinsulinemia [7, 8], increased levels of IGF [9, 10], and alterations in NF-κB [11] and PPARγ signaling [12], which may play a key role in the pathogenesis of CRC. Insulin resistance induces hyperinsulinemia, which activates PI3K/Akt/mTOR/S6K signaling pathway in cancer [26]. Additionally, elevated serum TG, a component of the TyG index, activates Akt signaling pathway through G protein-coupled receptor [27]. In fact, the gene expression of the PI3K/Akt/mTOR signaling axis in human colorectal cancer are significantly overexpressed compared to normal colonic tissues [28]. Moreover, some recent studies reported that insulin promotes colon cancer progression by upregulation of acyl coenzyme A: cholesterol acyltransferase1 [29], and increases the expression of vascular cell adhesion molecule-1 in intestinal tumor endothelial cells and produces proinflammatory state which promotes tumorigenesis [30]. Taken together, hyperinsulinemia caused by insulin resistance may contribute to the growth and progression of colorectal cancer. Insulin resistance is related with increased IGF-1 levels [9, 10]. IGF-1 activates IGF-1 receptor, which regulate cell proliferation, survival, and angiogenesis [31]. IGF-1 promotes to product vascular endothelial growth factor, which supports tumor growth [32]. In fact, the expression of IGF-1 and IGF-1 receptor increases with tumor size in colorectal cancer in a human study [33]. In addition, hyperglycemia enhances the cellular sensitivity to IGF-I, including increased cell proliferation and migration [34]. Hyperglycemia is reported to induce an increase in intranuclear NF-κB in human subjects [35]. NF-κB regulates a number of genes included in the process of cell proliferation, neoplasia, and metastasis. Moreover, two target genes for NF-κB such as cyclin D1 and cMyc take an important part in cell growth and proliferation [36]. In the carcinogenic process of CRC, the NF-κB signaling pathway is an important complex pathway. The changes of gene expression in signaling pathway by insulin resistance downregulated the genes with a positive role of immune response and upregulated the genes of pro-inflammatory, which induced potent immune response and inflammation [37]. Sarraf, et al. [38] demonstrated that the growth and differentiation of colon cancer cells can be modulated through PPARγ, and since then, many groups have reported the association between PPARγ signaling and CRC [39-41]. Kubota, et al. [42] demonstrated the association between PPARγ and insulin resistance in adipocyte. In addition, colorectal tumor is developed by the activation of PPARγ [43]. In addition, both serum plasma glucose and triglycerides levels are related with risk of CRC in human subjects [2, 6]. TyG index is composed of levels of triglyceride and glucose, and it is expected that TyG index is more useful risk marker of CRC. Our study also has some limitations. We did not perform colonoscopy to all participants. In addition, the proportion of the participants who received further examinations was approximately only 50% out of the participants whose fecal occult tests were positive. Therefore, there was a possibility that the number of incident CRC was underestimated. However, CRC incidence in this study was 0.4% and that available for all generations in Japan is 0.2% [44]. Therefore, underestimation of incident CRC might be smaller than expected. Lastly, in the present study, only the TyG index at the initial visit was included in the analysis, and we did not take into account factors of improvement and deterioration during the course of follow-up.

Conclusions

In conclusion, TyG index is a useful and accessible tool for predicting incident CRC. For early detection of CRC, we should encourage people with high TyG index, the cut-off value of which was 8.272 in our study, to undergo screening for CRC.
  42 in total

Review 1.  Insulin, insulin-like growth factors and colon cancer: a review of the evidence.

Authors:  E Giovannucci
Journal:  J Nutr       Date:  2001-11       Impact factor: 4.798

2.  The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.

Authors:  Masahide Hamaguchi; Takao Kojima; Noriyuki Takeda; Takayuki Nakagawa; Hiroya Taniguchi; Kota Fujii; Tatsushi Omatsu; Tomoaki Nakajima; Hiroshi Sarui; Makoto Shimazaki; Takahiro Kato; Junichi Okuda; Kazunori Ida
Journal:  Ann Intern Med       Date:  2005-11-15       Impact factor: 25.391

3.  Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice.

Authors:  A M Lefebvre; I Chen; P Desreumaux; J Najib; J C Fruchart; K Geboes; M Briggs; R Heyman; J Auwerx
Journal:  Nat Med       Date:  1998-09       Impact factor: 53.440

4.  Expression of IGF-1 and IGF-1R and their relation to clinicopathological factors in colorectal cancer.

Authors:  Ichitarou Shiratsuchi; Yoshito Akagi; Akihiko Kawahara; Tetsushi Kinugasa; Kansakar Romeo; Takefumi Yoshida; Yasuhiko Ryu; Yukito Gotanda; Masayoshi Kage; Kazuo Shirouzu
Journal:  Anticancer Res       Date:  2011-07       Impact factor: 2.480

5.  Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index. Risk Index Working Group, Harvard Center for Cancer Prevention.

Authors:  G A Colditz; K A Atwood; K Emmons; R R Monson; W C Willett; D Trichopoulos; D J Hunter
Journal:  Cancer Causes Control       Date:  2000-07       Impact factor: 2.506

6.  Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden.

Authors:  R Palmqvist; G Hallmans; S Rinaldi; C Biessy; R Stenling; E Riboli; R Kaaks
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

7.  Components of the metabolic syndrome and colorectal cancer risk; a prospective study.

Authors:  T Stocks; A Lukanova; M Johansson; S Rinaldi; R Palmqvist; G Hallmans; R Kaaks; P Stattin
Journal:  Int J Obes (Lond)       Date:  2007-09-18       Impact factor: 5.095

8.  PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas.

Authors:  Fausto Bogazzi; Federica Ultimieri; Francesco Raggi; Dania Russo; Renato Vanacore; Chiara Guida; Paolo Viacava; Denise Cecchetti; Giovanni Acerbi; Sandra Brogioni; Chiara Cosci; Maurizio Gasperi; Luigi Bartalena; Enio Martino
Journal:  Eur J Endocrinol       Date:  2004-06       Impact factor: 6.664

9.  Insulin resistance in vascular endothelial cells promotes intestinal tumour formation.

Authors:  X Wang; M-F Häring; T Rathjen; S M Lockhart; D Sørensen; S Ussar; L M Rasmussen; M M Bertagnolli; C R Kahn; C Rask-Madsen
Journal:  Oncogene       Date:  2017-05-01       Impact factor: 9.867

10.  Insulin promotes progression of colon cancer by upregulation of ACAT1.

Authors:  Xin Chen; Huiling Liang; Qibin Song; Ximing Xu; Dedong Cao
Journal:  Lipids Health Dis       Date:  2018-05-24       Impact factor: 3.876

View more
  8 in total

1.  A Machine Learning-Modified Novel Nomogram to Predict Perioperative Blood Transfusion of Total Gastrectomy for Gastric Cancer.

Authors:  Jiawen Zhang; Linhua Jiang; Xinguo Zhu
Journal:  Front Oncol       Date:  2022-04-11       Impact factor: 5.738

2.  Triglyceride-Glucose Index Is Not Associated With Lung Cancer Risk: A Prospective Cohort Study in the UK Biobank.

Authors:  Lijie Wang; Shucheng Si; Jiqing Li; Yunxia Li; Xiaolu Chen; Fuzhong Xue; Wangang Ren
Journal:  Front Oncol       Date:  2021-11-17       Impact factor: 5.738

3.  Relationship Between the Triglyceride Glucose Index and the Risk of First Stroke in Elderly Hypertensive Patients.

Authors:  Longlong Hu; Huihui Bao; Xiao Huang; Wei Zhou; Tao Wang; Lingjuan Zhu; Xi Liu; Minghui Li; Xiaoshu Cheng
Journal:  Int J Gen Med       Date:  2022-02-09

4.  Impact of Baseline and Trajectory of Triglyceride-Glucose Index on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus.

Authors:  Shi Tai; Liyao Fu; Ningjie Zhang; Ying Zhou; Zhenhua Xing; Yongjun Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-24       Impact factor: 5.555

Review 5.  Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents.

Authors:  Jelena Vekic; Aleksandra Zeljkovic; Aleksandra Stefanovic; Rosaria Vincenza Giglio; Marcello Ciaccio; Manfredi Rizzo
Journal:  Int J Mol Sci       Date:  2021-11-17       Impact factor: 6.208

6.  Are lipid ratios and triglyceride-glucose index associated with critical care outcomes in COVID-19 patients?

Authors:  Marzieh Rohani-Rasaf; Kosar Mirjalili; Akram Vatannejad; Maryam Teimouri
Journal:  PLoS One       Date:  2022-08-01       Impact factor: 3.752

7.  Association between the TyG index and TG/HDL-C ratio as insulin resistance markers and the risk of colorectal cancer.

Authors:  Tong Liu; Qingsong Zhang; Yiming Wang; Liying Cao; Hanping Shi; Xiangming Ma; Qi Zhang; Mengmeng Song
Journal:  BMC Cancer       Date:  2022-09-22       Impact factor: 4.638

8.  Ketogenic diets consumed during radio-chemotherapy have beneficial effects on quality of life and metabolic health in patients with rectal cancer.

Authors:  Rainer J Klement; Detlef Meyer; Stefan Kanzler; Reinhart A Sweeney
Journal:  Eur J Nutr       Date:  2021-06-27       Impact factor: 5.614

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.